FindTrial
Sign In

Efficacy and safety of Apremilast in Vogt-Koyanagi-Harada Disease

Efficacy and safety of Apremilast in Vogt-Koyanagi-Harada Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030238
Enrollment
Unknown
Registered
2020-02-25
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vogt-Koyanagi-Harada (VKH) Disease

Interventions

Case series:Apremilast

Sponsors

Zhongshan eye center of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Clinical symptoms meet the criteria of JAMA Ophthalmol. 2018 Sep 1;136(9):1025-1031

Exclusion criteria

Exclusion criteria: Malignancy or systemic infectious diseases, including hepatitis B or C infection or tuberculosis.

Design outcomes

Primary

MeasureTime frame
vision;anterior uveitis activity;Central thickness of macula;Fundus vessels leakage;—

Secondary

MeasureTime frame
Intraocular pressure;—

Countries

China

Contacts

Public ContactWenru Su

Zhongshan eye center of Sun Yat-sen University

suwr3@mail.sysu.edu.cn+86 13570364296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026